Overview
Hematology Regulatory Landscape
The regulatory environment for hematology therapies involves specialized requirements from FDA Office of Tissues and Advanced Therapies (OTAT), EMA Committee for Advanced Therapies (CAT), PMDA Cell and Gene Therapy Division. This guide maps each requirement to ArcaScience's platform capabilities, demonstrating how AI-driven benefit-risk analysis aligns with and accelerates regulatory compliance.
Regulatory Requirements
Key Requirements by Agency
FDA Requirements
- ✓ REMS requirements for CAR-T therapies
- ✓ Gene therapy long-term follow-up guidance (15 years)
- ✓ Expedited programs for hematologic malignancies
- ✓ CRS management guidance
- ✓ Post-marketing surveillance for cell therapies
EMA Requirements
- ✓ ATMP classification and BRA requirements
- ✓ Risk management plan for cell-based therapies
- ✓ Conditional marketing authorization for advanced therapies
- ✓ Long-term efficacy and safety follow-up requirements
PMDA Requirements
- ✓ Regenerative medicine product regulations
- ✓ Conditional and time-limited approval for cell therapies
- ✓ Post-marketing safety requirements for ATMPs
ArcaScience Alignment
How ArcaScience Maps to Hematology Requirements
Data Coverage
Hematology-specific data from 47+ global sources, pre-harmonized and validated for regulatory submissions.
AI Models
Hematology-trained AI models for adverse event classification, signal detection, and benefit quantification with regulatory validation.
Regulatory Outputs
Pre-formatted outputs aligned with FDA Office of Tissues and Advanced Therapies (OTAT) and EMA Committee for Advanced Therapies (CAT) submission requirements.
Download
Get the Full Hematology Regulatory Landscape
Complete the form below to receive the document via email.
Related Resources